Aptevo Therapeutics (APVO) Gross Margin (2015 - 2019)

Aptevo Therapeutics (APVO) posted Gross Margin of 32.06% for Q4 2019, down 42.82% sequentially from 56.06% in Q3 2019.

Aptevo Therapeutics (APVO) Gross Margin (2015 - 2019) Analysis & Trends

Aptevo Therapeutics has reported Gross Margin for 5 years, with the latest figure at 32.06% in Q4 2019.

Quarterly Gross Margin changed N/A year-over-year to 32.06% in Q4 2019, while the trailing twelve-month figure through Dec 2019 was 38.54% (changed N/A YoY) and the FY2019 annual result came in at 38.54%, down 1284.0% from the prior year.
Gross Margin fell to 32.06% in Q4 2019 per APVO's latest filing, from 56.06% in the prior quarter.
Over five years, Gross Margin peaked at 77.22% in Q1 2017 and troughed at 67.24% in Q2 2017.
A 5-year average of 36.26% and a median of 45.22% in 2019 frame the typical range for Gross Margin.
The sharpest annual moves came in 2017 and 2018: Gross Margin slumped 10283 bps in 2017, then surged 12765 bps in 2018.
Over 5 years, Gross Margin stood at 36.8% in 2015, then grew by 14 bps to 42.07% in 2016, then jumped by 66 bps to 69.67% in 2017, then dropped by 14 bps to 59.62% in 2018, then tumbled by 46 bps to 32.06% in 2019.
According to Business Quant data, Gross Margin over the past three periods registered 32.06%, 56.06%, and 18.68% for Q4 2019, Q3 2019, and Q2 2019 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	85.33%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	91.59%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	90.43%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	35.86%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	89.76%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	76.90%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	84.20%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	63.27%
10	Aptevo Therapeutics	3.30 Mn	-6.50 Mn	-	-

Download Data